Bitcoin halving
What does that mean?
$2.79T
Total marketcap
$119.67B
Total volume
BTC 49.87%     ETH 15.33%
Dominance

Zai Lab ZLAB Stock

16.02 USD {{ price }} -1.050031% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
1.59B USD
LOW - HIGH [24H]
15.96 - 16.43 USD
VOLUME [24H]
779.99K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-3.5 USD

Zai Lab Price Chart

Zai Lab ZLAB Financial and Trading Overview

Zai Lab stock price 16.02 USD
Previous Close 27.66 USD
Open 28.7 USD
Bid 0 USD x 900
Ask 0 USD x 800
Day's Range 27.73 - 29.65 USD
52 Week Range 20.98 - 53.95 USD
Volume 728.29K USD
Avg. Volume 630.93K USD
Market Cap 2.86B USD
Beta (5Y Monthly) 1.140845
PE Ratio (TTM) N/A
EPS (TTM) -3.5 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 78.35 USD

ZLAB Valuation Measures

Enterprise Value 1.83B USD
Trailing P/E N/A
Forward P/E -11.121094
PEG Ratio (5 yr expected) 0.11
Price/Sales (ttm) 12.361396
Price/Book (mrq) 2.7401345
Enterprise Value/Revenue 7.933
Enterprise Value/EBITDA -4.759

Trading Information

Zai Lab Stock Price History

Beta (5Y Monthly) 1.140845
52-Week Change 2.66%
S&P500 52-Week Change 20.43%
52 Week High 53.95 USD
52 Week Low 20.98 USD
50-Day Moving Average 33.88 USD
200-Day Moving Average 35.7 USD

ZLAB Share Statistics

Avg. Volume (3 month) 630.93K USD
Avg. Daily Volume (10-Days) 871.94K USD
Shares Outstanding 97.91M
Float 86.56M
Short Ratio 5.2
% Held by Insiders 0.088%
% Held by Institutions 76.76%
Shares Short 3.27M
Short % of Float N/A
Short % of Shares Outstanding 3.33%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -177.41%
Operating Margin (ttm) -170.52%
Gross Margin -56.086%
EBITDA Margin -166.69%

Management Effectiveness

Return on Assets (ttm) -18.44%
Return on Equity (ttm) -35.51%

Income Statement

Revenue (ttm) 231.11M USD
Revenue Per Share (ttm) 2.41 USD
Quarterly Revenue Growth (yoy) 34.39%
Gross Profit (ttm) -145386000 USD
EBITDA -385244000 USD
Net Income Avi to Common (ttm) -410036000 USD
Diluted EPS (ttm) -4.33
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 930.39M USD
Total Cash Per Share (mrq) 9.66 USD
Total Debt (mrq) 20.3M USD
Total Debt/Equity (mrq) 2.03 USD
Current Ratio (mrq) 8.609
Book Value Per Share (mrq) 10.39

Cash Flow Statement

Operating Cash Flow (ttm) -349801984 USD
Levered Free Cash Flow (ttm) -282261888 USD

Profile of Zai Lab

Country United States
State N/A
City Shanghai
Address Jinchuang Plaza
ZIP 201210
Phone 86 21 6163 2588
Website https://www.zailaboratory.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 2036

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Q&A For Zai Lab Stock

What is a current ZLAB stock price?

Zai Lab ZLAB stock price today per share is 16.02 USD.

How to purchase Zai Lab stock?

You can buy ZLAB shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Zai Lab?

The stock symbol or ticker of Zai Lab is ZLAB.

Which industry does the Zai Lab company belong to?

The Zai Lab industry is Biotechnology.

How many shares does Zai Lab have in circulation?

The max supply of Zai Lab shares is 99.21M.

What is Zai Lab Price to Earnings Ratio (PE Ratio)?

Zai Lab PE Ratio is now.

What was Zai Lab earnings per share over the trailing 12 months (TTM)?

Zai Lab EPS is -3.5 USD over the trailing 12 months.

Which sector does the Zai Lab company belong to?

The Zai Lab sector is Healthcare.

Zai Lab ZLAB included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16379.46 USD
-0.12
4.77B USD 16347.38 USD 16420.92 USD 4.77B USD
NASDAQ Global Market Composite NQGM 2283.98 USD
+0.52
2277.12 USD 2296.84 USD
NASDAQ Biotechnology NBI 4429.97 USD
-0.36
4426.59 USD 4461.88 USD
NASDAQ HealthCare IXHC 1011.84 USD
-0.04
1011.35 USD 1017.55 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Golden Dragon China Inde HXC 6117.19 USD
+0.3
6112.34 USD 6177.64 USD